The direct thrombin inhibitors (argatroban, bivalirudin and lepirudin) and the indirect Xa-inhibitor (danaparoid) increase fibrin network porosity and thus facilitate fibrinolysis.
The present study aimed to assess whether the fibrin network structure is modified by the direct thrombin-inhibitors lepirudin, argatroban or bivalirudin and by the indirect Xa-inhibitor danaparoid. Using an in vitro assay that imitates the physiological process of coagulation from thrombin generation to fibrin formation, we examined a normal plasma pool spiked with one of the inhibitors. At concentrations considered to be the plasma levels observed during therapy, almost no influence was detected for lepirudin despite clear-cut effects on "clotting time". However, argatroban, bivalirudin and danaparoid increased the fibrin gel permeability (Ks) to a similar extent. At concentrations higher than the "therapeutic" levels, the dose-response curve in the Ks assay became very steep for lepirudin while those were shallow for the others. In parallel with the drug-induced increases of Ks, larger network pores in 3D-microscopic images and significant shortenings in "clot lysis time" induced by addition of rtPA were observed. Recombinant factor VIII (rFVIII) added to danaparoid-treated samples profoundly counteracted the increase of Ks but had only a slight or no effect on the other drugs. Thus, in vitro, argatroban, bivalirudin and danaparoid have comparable anticoagulating effects, rendering the fibrin network more permeable and less resistant to fibrinolysis. For lepirudin, the steep dose-response curve supports previous clinical findings, i.e. this thrombin inhibitor has a narrow therapeutic window. Furthermore, our data suggest that the haemostatic agent, rFVIII, might be effective in treatment of bleeding complications induced by danaparoid.
He
Shu
S
Department of Clinical Sciences, Danderyd Hospital, Karolinska Institutet, Stockholm, Sweden. he_shu@yahoo.com
Blombäck
Margareta
M
Bark
Niklas
N
Johnsson
Hans
H
Wallén
N Hakan
NH
D000991:Antithrombins / Q000494:pharmacology*; D001120:Arginine / Q000031:analogs & derivatives; D002809:Chondroitin Sulfates / Q000494:pharmacology; D002850:Chromatography, Gel; D003871:Dermatan Sulfate / Q000494:pharmacology; D005169:Factor VIII / Q000378:metabolism; D065427:Factor Xa Inhibitors; D005337:Fibrin / Q000737:chemistry / Q000378:metabolism*; D005342:Fibrinolysis / Q000187:drug effects; D006496:Heparinoids / Q000494:pharmacology*; D006497:Heparan Sulfate / Q000494:pharmacology; D006629:Hirudins / Q000494:pharmacology; D006801:Humans; D066298:In Vitro Techniques; D018613:Microscopy, Confocal; D010446:Peptide Fragments / Q000494:pharmacology; D010875:Pipecolic Acids / Q000494:pharmacology; D010949:Plasma / Q000187:drug effects* / Q000378:metabolism; D016062:Porosity; D055503:Protein Multimerization; D011994:Recombinant Proteins / Q000494:pharmacology; D013449:Sulfonamides; D013927:Thrombosis / Q000378:metabolism; D010959:Tissue Plasminogen Activator / Q000378:metabolism
D000991:Antithrombins; D001120:Arginine; D002809:Chondroitin Sulfates; D003871:Dermatan Sulfate; D005169:Factor VIII; D065427:Factor Xa Inhibitors; D005337:Fibrin; D006496:Heparinoids; D006497:Heparan Sulfate; D006629:Hirudins; D010446:Peptide Fragments; D010875:Pipecolic Acids; D011994:Recombinant Proteins; D013449:Sulfonamides; D010959:Tissue Plasminogen Activator; C035838:danaparoid; C031942:argatroban; C074619:bivalirudin; C083544:lepirudin